Marqibo has annual sales potential of $100M+. This is TLON's estimate, and is conservative. The real money will be in Menadione which will have data available from it's Phase 2 study by mid 2013. This has an annual sales potential in the billions.
Your numbers are correct. However, the $100M+ is for the only initial approved indication. Other indications can be added to the label, plus there may be off label use. TLON's web site presentation said that the approval for all indications would result in revenue of several $ billion for Marqibo. Those other indications are now in different phases of trails but the the overall time frame is not given.